Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · IEX Real-Time Price · USD
0.280
-0.009 (-3.08%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Lyra Therapeutics Revenue
Lyra Therapeutics had revenue of $1.68M in the twelve months ending March 31, 2024, with 28.74% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $532.00K with 29.76% year-over-year growth. In the year 2023, Lyra Therapeutics had annual revenue of $1.56M with 14.31% growth.
Revenue (ttm)
$1.68M
Revenue Growth
+28.74%
P/S Ratio
10.16
Revenue / Employee
$19,091
Employees
88
Market Cap
17.07M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.56M | 195.00K | 14.31% |
Dec 31, 2022 | 1.36M | 1.08M | 378.25% |
Dec 31, 2021 | 285.00K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 1.24M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Aytu BioPharma | 93.76M |
Biotricity | 12.06M |
VBI Vaccines | 9.41M |
Synlogic | 3.21M |
Aeterna Zentaris | 2.37M |
Aptorum Group | 431.38K |
LYRA News
- 2 months ago - Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital - GlobeNewsWire
- 2 months ago - Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis - GlobeNewsWire
- 2 months ago - Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 months ago - Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Lyra Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire